Reata to Use IPO to Further Develop Bardoxolone Methyl as a Pulmonary Hypertension Therapy
Reata Pharmaceuticals, Inc., recently announced in a press release the pricing of its initial public offering of 5,500,000 shares of its Class A common stock at $11.00 per share, before underwriting discounts and commissions. The Irving, Texas-based clinical-stage biopharmaceutical company says it intends to use net proceeds from the offering…